Interaction of doxorubicin and its derivatives with DNA: Elucidation by resonance Raman and surface-enhanced resonance Raman spectroscopy

Biospectroscopy

Volumn 3, Issue 4, 1997, Pages 307-316

  Yan, Qing ^a   Priebe, Waldemar ^b   Chaires, Jonathan B ^c   Czernuszewicz, Roman S ^a  

^a University of Houston   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Doxorubicin; Intercalation; Resonance Raman; SERRS

Indexed keywords

EID: 0000313917     PISSN: 10754261     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6343(1997)3:4<307::AID-BSPY6>3.0.CO;2-0     Document Type: Article

References (44)

1. F. Arcamone, Doxorubicin: Anticancer Antibiotics, Academic Press, New York, 1981.
2. J. W. Lown, Ed. Anthracycline and Anthracenedione Based Anticancer Agents, Elsevier, Amsterdam, The Netherlands, 1988.
3. W. Priebe, Ed. Antracycline Antibiotics. Novel Analogues, Methods of Delivery, and Mechanisms of Action , American Chemical Society, Washington, DC, 1995.
4. M. Gigli, S. M. Doglia, J. M. Millot, L. Valentini, and M. Manfait, "Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry," Biochim. Biophys. Acta, 950, 13-20 (1988).
5. G. Capranico, F. Zunino, K. Kohn, and Y. Pommier, "Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytoxicity," Biochemistry, 29, 562-569 (1990).
6. U. Pindur, M. Haber, and K. Sattler, "Antitumor active drugs as intercalators of deoxyribonucleic acid," J. Chem. Educ., 70, 263-272 (1993).
7. E. M. Acton, G. L. Tong, C. W. Mosher, and R. L. Wolgemuth, "Intensely potent mopholinyl anthracyclines," J. Med. Chem., 27, 638-645 (1984).
8. C. E. Myers, J. R. F. Muindi, J. Zweier, and B. K. Sinha, "5-Iminodaunomycin: an anthracycline with unique properties," J. Biol. Chem., 262, 11571-11577 (1987).
9. J. R. Brown, "Doxorubicin and related anthracycline antibiotics," Progr. Med. Chem., 15, 125-136 (1978).
10. L. Gianni, B. J. Croden, amd C. E. Myers, "The biochemical basis of anthracycline toxicity and antitumor activity," in Reviews in Biochemical Toxicology, Vol. 5, ed. by E. Hodgson, J. R. Bend and R. M. Philpot, Elsevier Scientific Publishing Co., New York, 1983, pp. 1-82.
11. A. DiMarco, F. Arcamone, and F. Zunino, "Daunomycin and doxorubicin and structral analogues: biological activity and mechanism of action," in Antibiotics, ed. by J. W. Corcoran and F. E. Hahn, Springer-Verlag, Berlin, 1974, pp. 101-128.
12. W. Priebe, N. T. Van, and R. Perez-Soler, "Biological effects of deamination at C-3N. Evaluation of 3N-hydroxy-doxorubicin (Hydroxyrubicin)," J. Cancer Res. Clin. Oncol., 116 (Suppl., Part I), 439 (1990).
13. W. Priebe, N. Neamati, and R. Perez-Soler, "3N-Hydroxyesorubicin. Synthesis and antitumor activity," J. Antibiot., 43, 838-846 (1990).
14. W. Priebe, G. Grynkiewicz, N. Neamati, and R. Perez-Soler, "A facile method for preparation of 3-thio-sugars and 3-thio-glycols. Synthesis of 3N-mercapto-3N-deamino-doxorubicin," Tetrahedron Lett., 32, 3313-3316 (1991).
15. W. Priebe, N. Neamati, and R. Perez-Soler, "3N-Hydroxy-esorubicin halogenated at C-2N," J. Antibiot., 45, 386-393 (1992).
16. W. Priebe, N. T. Van, T. G. Burke, and R. Perez-Soler, "Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity," Anti-Cancer Drugs, 4, 37-48 (1993).
17. W. Priebe, and R. Perez-Soler, "Design and tumor targeting of anthracyclines able to overcome multi-drug resistance: a double-advantage approach," Pharmacol. Ther., 60, 215-324, (1993).
18. W. Priebe, P. Skibicki, and O. Varela, "Non-cross-resitant anthracyclines with reduced basicity and increased stability of the glycosidic bond," in Antracycline Antibiotics. Novel Analogues, Methods of Delivery, and Mechanisms of Action, ed. by W. Priebe, American Chemical Society, Washington, DC, 1995, pp. 14-46.
19. W. Priebe, "Mechanism of action-governed design of anthracycline antibiotics: a 'turn-off/turn-on' approach," Curr. Pharmac. Design, 1, 51-68 (1995).
20. C. A. Frederick, L. D. Willams, G. Ughetto, G. van der Marel, J. H. van Boom, A. Rich, and A. H.-J. Wang, "Structural comparison of anticancer drug-DNA complexes: doxorubicin and daunomycin," Biochemistry, 29, 2538-2549 (1990).
21. S. Neidle and M. R. Sanderson, "The interaction of daunomycin and doxorubicin with nucleic acids," in Molecular Aspects of Anti-cancer Drug DNA Action, ed. by S. Neidle and M. J. Waring, MacMillan Press, London, 1983, pp. 35-55.
22. Y. Nakata and A. J. Hopfinger, "Predicted mode of intercalation of doxorubicin with dinucleotide dimers," Biochem. Biophys. Res. Commun., 95, 583-588 (1980).
23. K.-X. Chen, N. Gresh, and B. Pullman, "A theoretical investigation on the sequence selective binding of daunomycin to double-stranded polynucleotides," J. Biomol. Struct. Dynam., 3, 445-466 (1985).
24. M. Manfait and T. Theophanides, "Drug-nucleic acid interactions," in Spectroscopy of Biological Systems, ed. by R. J. H. Clark and R. E. Hester, John Wiley & Sons Ltd., Chichester, 1986, pp. 311-346.
25. G. Smulevich and A. Feis, "Surface-enhanced resonance Raman spectra of doxorubicin, 11-deoxycarminomycin, their model chromophores, and their complexes with DNA," J. Phys. Chem., 90, 6388-6392 (1986).
26. I. R. Nabiev, K. V. Sokolov, and M. Manfait, "Surface-enhanced Raman spectroscopy and its biomedical applications," in Biomolecular Spectroscopy, Part A, ed. by R. J. H. Clark and R. E. Hester, John Wiley & Sons Ltd., Chichester, 1993, pp. 267-338.
27. H. Morjani, J.-F. Riou, I. R. Nabiev, F. Lavelle, and M. Manfait, "Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy," Cancer Res., 53, 4784-4790 (1993).
28. I. R. Nabiev, I. Chourpa, and M. Manfait, "Comparative studies of antitumor DNA intercalating agents, aclacinomycin and saintopin, by means of surface-enhanced Raman scattering spectroscopy," J. Phys. Chem., 98, 1344-1350 (1994).
29. D. Horton, W. Priebe, and O. Varela, "Synthesis and antitumor activity of 3N-deamino-3N-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs," J. Antibiot., 37, 853-858 (1984).
30. J. B. Chaires, N. Datagupta, and D. M. Crothers, "Studies on the interaction of anthracycline antibiotics and DNA: equilibrium binding studies," Biochemistry, 21, 3933-3940 (1982).
31. P. C. Lee, and D. J. Meisel, "Adsorption and surface-enhanced Raman of dyes on silver and gold sols," J. Phys. Chem., 86, 3391-3395 (1982).
32. M. A. Walters, "Spinning cell for low temperature resonance Raman spectra without Dewar losses," Appl. Spectrosc., 37, 299-302 (1983).
33. M. Manfait, L. Bernard, and T. Theophanides, "Resonance and preresonance Raman spectra of the antitumor drugs doxorubicin and daunorubicin," J. Raman Spectrosc., 11, 68-74 (1981).
34. L. Angeloni, G. Smulevich, and M. P. Marzocchi, "Absorption, fluorescence and resonance Raman spectra of doxorubicin and its complex with DNA," Spectrochim. Acta, 38, 213-217, (1982).
35. Y. Nonaka, M. Tsuboi, and K. Nakamoto, "Comparative study of aclacinomycin versus doxorubicin by means of resonance Raman spectroscopy," J. Raman Spectrosc., 21, 133-141 (1990).
36. L. E. Xodo, G. Manzini, J. Ruggiero, and F. Quadrifoflio, "On the interaction of daunomycin with synthetic alternating DNAs: sequence specificity and polyelectrolyte effects on the intercalation equilibrium," Biopolymers, 27, 1839-1857 (1988).
37. J. A. Shelnutt, "Structure of molecular complexes of copper uroporphyrin with aromatic heterocycles," J. Am. Chem. Soc., 103, 4275-4277 (1981).
38. J. A.Shelnutt, "Molecular complexes of copper uroporphyrin with aromatic acceptors," J. Phys. Chem., 87, 605-616 (1983).
39. E. Calendi, A. DiMarco, M. Reggiani, B. Scarpinato, and C. Valentini, "Interactions between daunomycin and nucleic acids," Biochim. Biophys. Acta, 103, 25-49 (1965).
40. M. Manfait, A. J. P. Alix, P. Jeannesson, J.-C. Jardillier, and T. Theophanides, "Interaction of doxorubicin with DNA as studied by resonance Raman spectroscopy," Nucleic Acids Res., 10, 3803-3816 (1982).
41. N. Husain, R. A. Agbaria, and I. M. Warner, "Spectroscopic analysis of the binding of doxorubicin to human α-1 acid glycoprotein," J. Phys. Chem., 97, 10857-10861 (1993).
42. E. Koglin, and J.-M. L. Sequaris, "Surface enhanced Raman scattering of biomolecules," Top. Curr. Chem., 134, 1-57 (1986).
43. J. B. Chaires, W. Priebe, D. E. Graves, and T. G. Burke, "Dissection of the free energy of anthracycline antibiotic binding to DNA: electrostatic contributions," J. Am. Chem. Soc., 115, 5360-5371 (1993).
44. J. B. Chaires, S. Satyanarayana, D. Suh, I. Fokt, T. Przewloka, and W. Priebe, "Parsing the free energy of anthracycline antibiotic binding to DNA," Biochemistry, 35, 2047-2053 (1996).